- Home
- A-Z Publications
- Current HIV Research
- Fast Track Listing
Current HIV Research - Online First
Description text for Online First listing goes here...
7
results
-
-
Navigating the COVID-19 Treatment Landscape: Efficacy and Side-Effects of Current Therapies against SARS-CoV-2
Available online: 28 April 2025More LessCoronavirus Disease 2019 (COVID-19), caused by the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China. Designated as an epidemic by the World Health Organization (WHO) on January 30, 2020, the virus quickly escalated to a global emergency, officially declared a pandemic in March 2020. With over 6 million recorded deaths and more than 200 identified sy Read More
-
-
-
Virological Failure And HIV-1 Drug Resistance in Indian Adults and Adolescents on Protease Inhibitor Based Second-line Antiretroviral Therapy: A Five-year Follow-up Study
Authors: Sumit Arora, Kuldeep Ashta, Nishant Raman, Charu Mohan, N Kisenjang, Vikram Sharma and Anirudh AnilkumarAvailable online: 14 April 2025More LessIntroduction In the changing HIV treatment landscape, the focus shifts to persons living with HIV (PLH) experiencing virological non-suppression on second-line antiretroviral therapy (ART). This includes understanding viral genetic profiles, antiretroviral susceptibility, and the effectiveness of protease inhibitors (PIs) amid evolving dolutegravir-based regimen recommendations. Methods In this retrospective study, PLH with first Read More
-
-
-
Fc Functions and Anti-HIV Neutralizing Antibodies: A Perspective
Authors: Hillary A Vanderven and Stephen J KentAvailable online: 25 March 2025More LessControversy exists around the relative merits of Fc functions in controlling or preventing HIV-1 infection. Proponents point to general correlations of Fc functions with control of HIV, indicating that non-neutralizing antibodies could force immune escape, as observed in the early experiments with Fc mutants of the b12-neutralizing monoclonal antibody. Nay-sayers point to the primary role of neutralization in the control of HIV, the Read More
-
-
-
The Germline Targeting Vaccine Concept: Overview and Updates from HIV Pre-Clinical and Clinical Trials
Available online: 21 February 2025More LessAn effective HIV-1 vaccine should elicit diverse immune responses, including broadly neutralizing antibodies (bNAbs). Such antibodies recognize regions of the viral envelope glycoprotein (Env) that are conserved among the diverse HIV-1 clades and strains. They are isolated from people living with HIV-1 to protect animals from experimental viral exposure and reduce HIV-1 acquisition in clinical settings. However, despite efforts Read More
-
-
-
Correlation of Total Lymphocyte Count, Human Immunodeficiency Virus Infection Status, and Tuberculosis Lesions on Chest X-ray: Can TLC Be an Alternative to CD4?
Authors: Vicky Septian Ariska, Netty Delvrita Lubis and Tambar KembarenAvailable online: 14 February 2025More LessBackground Tuberculosis (TB), caused by Mycobacterium tuberculosis, often becomes a comorbidity in individuals infected with Human Immunodeficiency Virus (HIV), the cause of Acquired Immunodeficiency Syndrome (AIDS). HIV-positive individuals have a 30-fold higher risk of contracting TB compared to non-HIV individuals. Assessment of HIV-TB disease progression commonly relies on measuring CD4 cell cou Read More
-
-
-
Integrated Computational Analysis of C-2 Substituted Pyrazolopyrimidine and Amide Isosteres ALLINI: 3D-QSAR, Molecular Docking, and ADMET Studies
Authors: Aakanksha Kunwar, Gondaliya Krishna N., Vijay M. Khedkar and Prakash C. JhaAvailable online: 12 February 2025More LessIntroduction The rapid increase in incidences of drug resistance and off-target toxicity in the case of Human Immunodeficiency Virus (HIV) has increased the demand for drugs with fewer side effects. HIV-1 Integrase (IN) is a promising target that helps integrate viral DNA with human DNA. It acts as a target for strand transfer inhibitors. However, the emergence of resistant mutations in the proteins necessitates the exploratio Read More
-
-
-
Prevalence of Metabolic Syndrome in Iranian Adults Receiving Antiretroviral Treatment for HIV
Available online: 11 February 2025More LessBackground The increased risk of metabolic syndrome (MetS) and its subcomponents among people living with HIV/AIDS, especially in developing countries, is well documented with the global pooled prevalence of the related risk factors in this population. Objective This study aimed to explore the prevalence of MetS among Iranian People living with HIV according to the ATP III and Iranian criteria. Methods The cross-sectional st Read More
-